An international pharmaceutical company: cost-utility model for international price and reimbursement applications

The project included building an international pharmaceutical company a cost-utility model to estimate quality-of-life benefits of a drug in relation to its cost changes. Modelling was carried out by collecting statistics from Finnish registers and international publications on the use of social and health care services, and on the quality-of-life impacts of the new treatment. Based on the collected data, effects of the drug on the care pathway and on the health of the patient were modelled.

The cost-utility model was built for international purposes, and its rights sold in their entirety. The customer plans to use the model in price and reimbursement related matters in Europe and in the United States.